Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.20 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
We initiate coverage on Exagen with a Buy rating, citing a promising turnaround with growing diagnostics, improved margins, and new biomarker tests for lupus and RA. Despite a rocky history, Exagen's recent momentum, modest valuation, and potential upside from new products make it an attractive long-term speculative buy. Financially, Exagen reported $55.6 million in 2024 revenue, improved margins, and expects positive adjusted EBITDA by Q4 2025, supported by new product launches.
Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript
Exagen Inc. (NASDAQ:XGN ) Q4 2024 Results Conference Call March 11, 2025 8:30 AM ET Company Participants Ryan Douglas - Investor Relations John Aballi - President & Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Mark Massaro - BTIG Dan Brennan - TD Cowen Andrew Brackmann - William Blair Matthew Parisi - KeyBanc Operator Greetings, and welcome to Exagen Inc. Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Exagen (XGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript
Exagen, Inc. (NASDAQ:XGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Ryan Douglas – IR John Aballi - President & CEO Jeffrey Black - CFO Conference Call Participants Mark Massaro – BTIG Daniel Brennan - TD Cowen Kyle Mikson - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Andrew Brackmann - William Blair Operator Greetings. Welcome to the Exagen Inc. Third Quarter 2024 Earnings Call.
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.31 per share a year ago.
Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for Exagen (XGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Exagen (XGN) Shows Fast-paced Momentum But Is Still a Bargain Stock
Exagen (XGN) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out?
Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Fast-paced Momentum Stock Exagen (XGN) Is Still Trading at a Bargain
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.
Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
